Detalles de la búsqueda
1.
Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results.
J Card Fail
; 30(1): 104-110, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37072105
2.
Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting.
Mol Ther
; 31(3): 866-874, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36528793
3.
Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans.
Drug Metab Dispos
; 51(4): 451-463, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36639243
4.
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF.
JACC Heart Fail
; 11(7): 775-787, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37140510
5.
Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study.
Int J Cardiol
; 365: 34-40, 2022 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35842004
6.
Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.
Clin Drug Investig
; 41(10): 895-905, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34546534
7.
Drug-induced myocardial dysfunction - recommendations for assessment in clinical and pre-clinical studies.
Expert Opin Drug Saf
; 19(3): 281-294, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32064957
Resultados
1 -
7
de 7
1
Próxima >
>>